Insider buying last 90 days
No open-market insider purchases were filed for CORT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every CORT insider filing, plotted on the chart in Gekko.Open CORT in Gekko
NASDAQ: CORT
Corcept Therapeutics (CORT) Stock Analysis & Forecast
Sep 28 close
$115.63−0.47 (−0.4%)
Gekko Brief
AI summaryThis week's news for Corcept centers on regulatory and leadership developments alongside routine insider activity. The CHMP recommended approval of relacorilant for platinum-resistant ovarian cancer in the EU, with an EC decision expected in Q4 2026, and a related CHMP opinion backs Lifyorli combined with nab-paclitaxel for the same indication. Separately, the company announced a leadership transition in its Endocrinology division, with Justin Gunn succeeding Sean Maduck as President effective October 1, while Maduck continues as a senior commercial adviser. An oncology division president also sold $29,842 in stock under a pre-arranged 10b5-1 plan.
CORT closed at $115.63, down 0.4%, sitting above both its 50-day average of $111.29 and its 200-day average of $69.36, with the shorter average above the longer one. The GekkoIndex reads 53.7, placing the stock in the Neutral zone, down 2.3 over five days. Price sits 13.7% above the Gekko Fair Value of $101.68.
Corcept's next earnings report is scheduled for 4 November 2026, after the close, 36 days away and outside a typical 20-trading-day holding window. The prior quarter saw a 25.6% reaction following an EPS beat. No insider, Congress or unusual options activity appears in the respective windows. Seasonally, the next 20 trading days have averaged -1.6% over five years, rising in three of them, a pattern worth noting alongside the current gap to fair value.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Corcept Therapeutics price vs fair value
Close $115.63200-day averageGekko Fair Value $101.68
Corcept Therapeutics quick facts
- Market cap
- $12.50B
- P/E ratio
- 252.2
- Forward P/E
- 19.3
- EPS, TTM
- $0.47
- Revenue, TTM
- $830.8M
- Profit margin
- 6.6%
- Dividend yield
- —
- Beta
- 0.45
- Volume
- 1.14M avg 1.70M
- 1-year return
- +39.8%
- Typical daily move
- ±4.7%
- Typical 20-day move
- ±9.9%
- 50-day average
- $111.29
- 200-day average
- $69.36
- Next earnings
- Nov 4 after close
- Shares outstanding
- 108.1M
Corcept Therapeutics swing-trade checklist
Corcept Therapeutics scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $115.63 is above the 50-day ($111.29) and 200-day ($69.36) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
53.7, Neutral
Reading 53.7 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
13.7% above
Price is 13.7% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 36 days
Next report Nov 4, 2026, 36 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
−1.6% on average
From this point in the calendar, the next 20 trading days averaged −1.6% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Corcept Therapeutics stock chart and price history
Corcept Therapeutics closed at $115.63 on Sep 28, 2026, +39.8% over the past year, inside a 52-week range of $28.66 to $126.38.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −1.1%
- 3 months
- +31.6%
- 6 months
- +207.5%
- 1 year
- +39.8%
The full CORT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CORT in Gekko
Follow Corcept Therapeutics through every session
Put CORT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track CORT in GekkoFree for 7 days. No credit card required.
About Corcept Therapeutics
Corcept Therapeutics focuses on treatments for patients dealing with serious hormonal, cancer-related, and mental health conditions, marketing its products within the United States. Its main approved treatment is Korlym, a mifepristone tablet taken once each day, used to address elevated blood sugar linked to excess cortisol in adults facing endogenous Cushing's syndrome, especially those managing type 2 diabetes or impaired glucose tolerance who are not candidates for surgery or have not benefited from it.
Alongside this marketed treatment, Corcept continues research into new therapies. One candidate, relacorilant, is being tested as a standalone option for Cushing's syndrome and also paired with nab-paclitaxel, a combination that has finished Phase II study for ovarian cancer that has spread and is under review for other illnesses tied to elevated cortisol levels. Separate efforts target selective cortisol modulators meant for prostate cancer that resists standard hormone therapy and for weight gain linked to antipsychotic drugs, together with laboratory research into a gene expression assay tied to FKBP5.
Corcept Therapeutics shares trade on the NASDAQ under the ticker CORT.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- corcept.com
Corcept Therapeutics GekkoIndex: the smart money zone
Corcept Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.7, in the Neutral zone, down 2.3 points over five sessions.
53.7Neutral
Down 2.3 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 20 | +0.4% | +7.8% | ||
| Accumulation | 166 | +2.1% | +11.7% | ||
| Neutral (current zone) | 407 | +2.0% | +5.6% | ||
| Distribution | 75 | −0.3% | +3.9% | ||
| Selling | 4 | Too few readings yet | |||
Average CORT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the CORT price, zone by zone.Track CORT in Gekko
Is Corcept Therapeutics stock overvalued? Gekko Fair Value
Corcept Therapeutics trades 13.7% above Gekko Fair Value of $101.68, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Corcept Therapeutics shares are worth, recalculated every trading day.
$101.68
Gekko Fair Value, Sep 26, 2026
13.7% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open CORT in Gekko
Corcept Therapeutics insider and Congress trading
No open-market insider purchases were filed for Corcept Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in CORT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for CORT, plotted on the chart in Gekko.Open CORT in Gekko
Buybacks
Corcept Therapeutics has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $11.46M
- As a share of market cap
- 0.09%
- Trailing four quarters
- $96.22M
From company filings.
Corcept Therapeutics earnings: next date and track record
Corcept Therapeutics reports on Nov 4, 2026, after the close (36 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 36 days away
- EPS estimate
- $0.81
- Revenue estimate
- $323.9M
4 of 8reports beat the EPS estimate
±6.2%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 29, 2026 AI summary
- What they said
- Corcept Therapeutics reported Q2 2026 revenue of $256 million, a 32% year-over-year increase. Korlym and authorized generic revenue totaled $208.6 million, while newly launched Lifyorli contributed $47.6 million in its first quarter. Net income rose to $43 million from $35 million prior year. Cash and investments stood at $545 million. Catalyst and MOMENTUM trials demonstrated 24-27% hypercortisolism prevalence in difficult-to-treat diabetes and resistant hypertension patients.
- Guidance
- Full-year 2026 revenue guidance raised to $1.1-$1.2 billion. Management targets Cushing's syndrome revenue of at least $2 billion annually by end of decade, expanding to $3-$5 billion in 2030 following anticipated relacorilant approval after December 17 PDUFA date.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 29, 2026 | $0.36 est −$0.04 | $256.1M est $221.1M | +25.6% |
| Apr 30, 2026 | −$0.30 est −$0.14 | $164.9M est $185.3M | +10.4% |
| Feb 24, 2026 | $0.20 est $0.25 | $202.1M est $254.9M | +2.5% |
| Nov 4, 2025 | $0.16 est $0.18 | $207.6M est $255.3M | +3.3% |
| Jul 31, 2025 | $0.29 est $0.19 | $194.4M est $244.6M | −1.3% |
| May 5, 2025 | $0.17 est $0.14 | $157.2M est $216.7M | −2.8% |
| Feb 26, 2025 | $0.26 est $0.42 | $181.9M est $200.1M | −2.3% |
| Oct 30, 2024 | $0.41 est $0.28 | $182.5M est $198.0M | +1.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Corcept Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Corcept Therapeutics is $141.00, +21.9% from the last close, from 5 firms rating the stock in the last 90 days.
$141.00consensus 12-month target, +21.9% from the last close
Now $115.63Avg $141.00
Low $50High $165
Each firm’s latest rating in the last 90 days: 5 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 18 | H.C. Wainwright | $165 | +42.7% |
| Aug 21 | Piper Sandler | $165 | +42.7% |
| Aug 18 | Truist Financial | $164 | +41.8% |
| Aug 13 | Canaccord Genuity | $161 | +39.2% |
| Jul 30 | Piper Sandler | $165 | +42.7% |
+5.6%average 20-day move after past Neutral readings
−1.6%average move over the next 20 trading days in the last 5 years
±4.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Corcept Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Corcept Therapeutics averaged −1.6% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.1% | 3 of 5 |
| Next 10 trading days | +1.0% | 4 of 5 |
| Next 15 trading days | +3.3% | 3 of 5 |
| Next 20 trading days | −1.6% | 3 of 5 |
| Next 30 trading days | +6.2% | 3 of 5 |
For scale, CORT’s typical 20-trading-day move in either direction is about 9.9%.
Corcept Therapeutics market cap and key statistics
Corcept Therapeutics’s market cap is $12.50B, with a P/E ratio of 252.2 and revenue of $830.8M over the last twelve months.
Valuation
- Market cap
- $12.50B
- P/E ratio
- 252.2
- Forward P/E
- 19.3
- EPS, TTM
- $0.47
- Gekko Fair Value
- $101.68
Trading
- Volume
- 1.14M
- Avg volume, 20 days
- 1.70M
- 52-week high
- $126.38
- 52-week low
- $28.66
- Shares outstanding
- 108.1M
Financials
- Revenue, TTM
- $830.8M
- Profit margin
- 6.6%
- Return on equity
- 8.2%
- Quarterly earnings growth, YoY
- +24.1%
Risk and income
- Beta
- 0.45
- Typical daily move
- ±4.7%
- Typical 20-day move
- ±9.9%
Corcept Therapeutics stock news this week
Coverage of Corcept Therapeutics this week reads positive: 4 positive, 2 neutral and 0 negative headlines.
- Corcept Therapeutics’ oncology president sells $29,842 in stockInvesting.com, Sep 28
- Corcept Therapeutics Announces New Endocrinology Division PresidentThe Globe and Mail, Sep 25
- Does EU Ovarian Cancer Backing Change The Bull Case For Corcept Therapeutics Stock?Simply Wall Street, Sep 24
- Corcept Announces Planned Leadership TransitionBusiness Wire, Sep 23
- Corcept Names Justin Gunn President of Endocrinology as Sean Maduck Retirescitybiz, Sep 23
- Corcept Therapeutics' Sean Maduck to Resign as President of Corcept Endocrinology, to Serve as ConsultantTradingView, Sep 23
Corcept Therapeutics peers
Corcept Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Corcept Therapeutics stock FAQ
What is Corcept Therapeutics’s market cap?
Corcept Therapeutics’s market cap is $12.50B at the Sep 28, 2026 close of $115.63, with 108.1M shares outstanding. The shares trade on a P/E ratio of 252.2.
What is the Corcept Therapeutics stock forecast?
The consensus analyst 12-month price target for Corcept Therapeutics is $141.00, +21.9% from the last close. Of the 5 firms that rated the stock in the last 90 days, 4 rate it a buy, 0 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Corcept Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Corcept Therapeutics is overvalued: the Sep 28, 2026 close of $115.63 is 13.7% above Gekko Fair Value of $101.68. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Corcept Therapeutics report earnings next?
Corcept Therapeutics is expected to report on Nov 4, 2026, after the market closes (36 days away). Analysts expect earnings of $0.81 per share on revenue of $323.9M. Corcept Therapeutics beat the earnings estimate in 4 of its last 8 reports, moving 6.2% on average across the report.
What is Corcept Therapeutics’s 52-week high and low?
Corcept Therapeutics’s 52-week high is $126.38 and its 52-week low is $28.66; it closed at $115.63 on Sep 28, 2026, +39.8% over the past year.
Is Corcept Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and seasonality) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Corcept Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.